Regeneron Pharmaceuticals (REGN) saw its stock climb 2.6% on Thursday, buoyed by a landmark U.S. drug-pricing agreement and the announcement that its newly approved gene therapy, Otarmeni, will be provided free of charge in the United States. The shares closed at $766.02, marking gains for both the week and the month, though the stock remains down 1.3% year-to-date.
The rally comes as Wall Street analysts reaffirm their confidence in the biotech firm. Raymond James reiterated its Outperform rating and a price target of $910, while Cantor Fitzgerald maintained its Overweight rating and $800 target. The consensus among analysts is a Moderate Buy, reflecting cautious optimism about Regeneron's pipeline and policy developments.
Drug-Pricing Deal and Policy Implications
Regeneron's agreement with the U.S. government includes cutting Medicaid prices by benchmarking them to those in other developed nations and pegging future U.S. drug prices to international levels. The company also committed to offering Praluent on TrumpRx.gov at a most-favored-nation price, which is the lowest price paid by comparable wealthy countries. CEO Leonard Schleifer argued that U.S. patients and taxpayers have "shouldered a disproportionate share" of biotech innovation costs, and this deal aims to narrow the global price gap without stifling innovation.
This move places Regeneron as the last holdout among 17 pharmaceutical firms that participated in Trump-era negotiations, according to Reuters. Competitors like Pfizer, Eli Lilly, and Amgen had previously accepted similar price reductions. However, the complete terms of the agreement have not been fully disclosed, leaving some uncertainty in the market.
Otarmeni Gene Therapy: A Breakthrough
Regeneron announced that Otarmeni, a gene therapy targeting severe OTOF-related genetic hearing loss, received accelerated approval from the FDA. This marks the first approval for a dual adeno-associated virus vector-based gene therapy for this indication. In clinical trials, 80% of evaluable patients demonstrated hearing improvements. The therapy will be offered at no cost in the U.S., a significant move that could set a precedent for access to cutting-edge treatments. Dr. Eliot Shearer, an otolaryngologist at Boston Children's Hospital, described the approval as "a new era" for treating genetic hearing loss. Regeneron estimates that approximately 50 U.S. newborns are affected by OTOF-related hearing loss each year.
Dupixent Approval and Pipeline Progress
In addition to these developments, Regeneron's blockbuster drug Dupixent, developed with Sanofi, received FDA approval for use in children aged two to 11 with chronic spontaneous urticaria. Sanofi's Alyssa Johnsen highlighted the "limited treatment options" that have left these young patients underserved. This approval expands Dupixent's already broad label and could drive further revenue growth.
Raymond James also highlighted Regeneron's C5 complement program, including cemdisiran and pozelimab, with key catalysts expected in the fourth quarter of 2026, including an FDA decision in generalized myasthenia gravis and upcoming data readouts across other indications.
Valuation and Market Context
Regeneron's valuation remains a topic of debate. According to Simply Wall St, a discounted cash flow model suggests the shares are undervalued. However, a price-to-earnings approach places the stock at the biotech industry average and below its direct peer group. The company faces headwinds from legacy products like Eylea, which continues to feel pressure from competitors. Risks also persist: the FDA noted that its backing for Otarmeni could hinge on lasting hearing gains and confirmed benefits for speech and quality of life.
Investors are now looking ahead to Regeneron's first-quarter earnings report, due before the market opens on April 29. The stock's recent jump has intensified the debate over whether pipeline catalysts and policy tailwinds can sustain the rally. With a batch of regulatory and policy headlines dropped just ahead of earnings, the upcoming results will be critical in determining whether these moves translate into long-term value.
